aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
October 06, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
October 01, 2021 08:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 20, 2021 16:07 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 16, 2021 16:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock
September 16, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma Announces Proposed Public Offering of Common Stock
September 15, 2021 16:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
September 13, 2021 07:30 ET
|
aTyr Pharma, Inc.
Pangu’s basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical...
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
September 13, 2021 07:30 ET
|
aTyr Pharma, Inc.
Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the...
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
August 10, 2021 16:00 ET
|
aTyr Pharma, Inc.
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m....
aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
August 10, 2021 08:00 ET
|
aTyr Pharma, Inc.
Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE)...